Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
2, 719 (CRC Press, 2006)
Severe gastrointestinal conditions : Patients with gastrointestinal conditions such as gastroparesis or inflammatory bowel disease must exercise caution
Individual response varies, so choose a time that helps you manage side effects most effectively
Weight loss treatment should be personalized
At Biohackr Health, we are proud of our many success stories
US$ 25.35
US$ 28.51
US$ 29.64
US$ 23.25
US$ 26.86
US$ 22.62
US$ 23.39
US$ 29.96
US$ 25.30
US$ 23.46
